References - Homocysteine in Protein Structure/Function and Human Disease - page 133

38. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma
homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346
(7):476-83.
39. Daly S, Cotter A, Molloy AE, Scott J. Homocysteine and folic acid: implications for
pregnancy. Semin Vasc Med. 2005;5(2):190-200.
40. Gjesdal CG, Vollset SE, Ueland PM, Refsum H, Drevon CA, Gjessing HK, et al. Plasma total
homocysteine level and bone mineral density: the Hordaland Homocysteine Study. Arch
Intern Med. 2006;166(1):88-94.
41. Perla-Kajan J, Twardowski T, Jakubowski H. Mechanisms of homocysteine toxicity in
humans. Amino Acids. 2007;32(4):561-72.
42. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233-41.
43. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2):115-26.
44. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost.
2005;3(8):1646-54.
45. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, et al. Hyperhomocysteinemia
enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin
Invest. 2001;107(6):675-83.
46. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. The natural
history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet.
1985;37(1):1-31.
47. Strauss KA, Morton DH, Puffenberger EG, Hendrickson C, Robinson DL, Wagner C, et al.
Prevention of brain disease from severe 5,10-methylenetetrahydrofolate reductase deficiency.
Mol Genet Metab. 2007;91(2):165-75.
48. Lawrence de Koning AB, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its
role in the development of atherosclerosis. Clin Biochem. 2003;36(6):431-41.
49. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, et al. Effect of 3-year
folic acid supplementation on cognitive function in older adults in the FACIT trial: a
randomised, double blind, controlled trial. Lancet. 2007;369(9557):208-16.
50. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin intervention for stroke prevention
trial: an efficacy analysis. Stroke. 2005;36(11):2404-9.
51. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering
with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567-77.
52. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine
lowering and cardiovascular events after acute myocardial infarction. N Engl J Med.

2006;354(15):1578-88.
53. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementa-
tion in stroke prevention: a meta-analysis. Lancet. 2007;369(9576):1876-82.
54. Hankey GJ, Eikelboom JW, Yi Q, Lees KR, Chen C, Xavier D, et al. Antiplatelet therapy and
the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-
hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol.
2012;11:512-20.
55. Ebbing M, Bonaa KH, Arnesen E, Ueland PM, Nordrehaug JE, Rasmussen K, et al. Com-
bined analyses and extended follow-up of two randomized controlled homocysteine-lowering
B-vitamin trials. J Intern Med. 2010;268(4):367-82.
56. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, et al. Homocys-
teine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive
impairment: a randomized controlled trial. PLoS One. 2010;5(9):e12244.
57. de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of
homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized
controlled trial. Int J Geriatr Psychiatry. 2012;27(6):592-600.
58. Zhang C, Cai Y, Adachi MT, Oshiro S, Aso T, Kaufman RJ, et al. Homocysteine induces
programmed cell death in human vascular endothelial cells through activation of the unfolded
protein response. J Biol Chem. 2001;276(38):35867-74.